{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:01:12Z","timestamp":1787065272349,"version":"build-2736575974"},"reference-count":28,"publisher":"Impact Journals, LLC","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2023,9,30]]},"DOI":"10.18632\/aging.205035","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T09:53:11Z","timestamp":1695030791000},"page":"9561-9571","source":"Crossref","is-referenced-by-count":13,"title":["Impact of liver metastases status on survival outcomes of first-line immunotherapy in extensive stage small cell lung cancer: a systematic review and meta-analysis"],"prefix":"10.18632","volume":"15","author":[{"given":"Yan","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Jiangbin Hospital of Guangxi Zhuang Autonomous Region, Nanning 530000, Guangxi, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, Guangxi, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui-Yun","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Respiratory Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, Guangxi, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Bin","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, Guangxi, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.","volume":"7","author":"Bray","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(11)60165-7","article-title":"Small-cell lung cancer.","volume":"37","author":"De Ruysscher","year":"2011","journal-title":"Lancet"},{"key":"3","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1200\/JCO.2015.63.7918","article-title":"Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline.","volume":"3","author":"Giaccone","year":"2015","journal-title":"J Clin Oncol"},{"key":"4","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/1759-7714.14289","article-title":"Clinical characteristics and prognostic model for extensive-stage small cell lung cancer: A retrospective study over an 8-year period.","volume":"1","author":"Wang","year":"2022","journal-title":"Thorac Cancer"},{"key":"5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer.","volume":"7","author":"Sage","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"6","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1200\/JCO.2016.67.6601","article-title":"Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.","volume":"3","author":"Horn","year":"2016","journal-title":"J Clin Oncol"},{"key":"7","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.","volume":"3","author":"Luft","year":"2020","journal-title":"J Clin Oncol"},{"key":"8","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.","volume":"32","author":"Bai","year":"2022","journal-title":"JAMA"},{"key":"9","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.","volume":"39","author":"Ponce","year":"2019","journal-title":"Lancet"},{"key":"10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.","volume":"2","author":"Poltoratskiy","year":"2021","journal-title":"Lancet Oncol"},{"key":"11","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"2","author":"Gong","year":"2022","journal-title":"Lancet Oncol"},{"key":"12","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.","volume":"37","author":"Lam","year":"2018","journal-title":"N Engl J Med"},{"key":"13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3978\/j.issn.2225-319X.2015.02.04","article-title":"Systematic review and meta-analysis: techniques and a guide for the academic surgeon.","volume":"4","author":"Yan","year":"2015","journal-title":"Ann Cardiothorac Surg"},{"key":"14","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"33","author":"Altman","year":"2009","journal-title":"BMJ"},{"key":"15","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"34","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"16","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1200\/JCO.20.02212","article-title":"Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.","volume":"3","author":"Percent","year":"2021","journal-title":"J Clin Oncol"},{"key":"17","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/ng.2405","article-title":"Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer.","volume":"4","author":"Bhatt","year":"2012","journal-title":"Nat Genet"},{"key":"18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer.","volume":"52","author":"Jahchan","year":"2015","journal-title":"Nature"},{"key":"19","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1111\/1759-7714.13698","article-title":"Efficacy and safety of PD-1\/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.","volume":"1","author":"Cheng","year":"2020","journal-title":"Thorac Cancer"},{"key":"20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40487-021-00182-0","article-title":"Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis.","volume":"1","author":"Isla","year":"2022","journal-title":"Oncol Ther"},{"key":"21","doi-asserted-by":"publisher","first-page":"6662344","DOI":"10.1155\/2021\/6662344","article-title":"Combination of the EP and Anti-PD-1 Pathway or Anti-CTLA-4 for the Phase III Trial of Small-Cell Lung Cancer: A Meta-Analysis.","volume":"202","author":"Zhu","year":"2021","journal-title":"J Oncol"},{"key":"22","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00262-021-03052-w","article-title":"Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience.","volume":"7","author":"Hong","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"23","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.26355\/eurrev_202208_29525","article-title":"Efficacy of addition immune checkpoint inhibitors to chemotherapy as first-line treatment for small cell lung cancer patients with liver or brain metastases: a systematic review and meta-analysis.","volume":"2","author":"Tong","year":"2022","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"24","doi-asserted-by":"publisher","first-page":"978069","DOI":"10.3389\/fonc.2022.978069","article-title":"Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis.","volume":"1","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/cmi.2015.112","article-title":"Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells.","volume":"1","author":"Tiegs","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"26","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1093\/jjco\/hyd139","article-title":"Prognostic factors in advanced non-small cell lung cancer: elevated serum levels of neuron specific enolase indicate poor prognosis.","volume":"3","author":"Harada","year":"2000","journal-title":"Jpn J Clin Oncol"},{"key":"27","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination.","volume":"2","author":"Zhou","year":"2021","journal-title":"Nat Med"},{"key":"28","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1002\/cncr.33142","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.","volume":"12","author":"Gadgeel","year":"2020","journal-title":"Cancer"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.205035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T15:19:45Z","timestamp":1696519185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.205035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":28,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2023,9,30]]}},"alternative-id":["205035","37724893"],"URL":"https:\/\/doi.org\/10.18632\/aging.205035","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,18]]}}}